Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Blink Tears eye in a multidose bottle · 1 trial · 1 indication
Monocular visual acuity was measured at distance (4meter) using a logMAR (Logarithm of Minimal Angle of Resolution) scale under high luminance high contrast lighting conditions. VA was assessed using ETDRS (Early Treatment Diabetic Retinopathy Study) charts. Letter-by-letter results calculated the visual acuity score for each chart read. LogMAR scores closer to zero, or below zero, indicate a better visual acuity. A logMAR visual performance score of 0.0 is equivalent to Snellen visual acuity of 20/20.
| Arm | Type | Description |
|---|---|---|
| Test/Control | EXPERIMENTAL | Eligible subjects who are habitual soft contact lens wearers will be randomized into the Test/Control sequence, to receive 1-2 drops on each eye (right eye followed by left eye) over soft spherical contact lenses, over two wear periods (test then control). A washout period of 90 minutes between eyedrop instillations will occur. The second eyedrop as per the randomization schedule will follow the same procedure as previously stated. |
| Control/Test | EXPERIMENTAL | Eligible subjects who are habitual soft contact lens wearers will be randomized into the Control/Test sequence, to receive 1-2 drops on each eye (right eye followed by left eye) over soft spherical contact lenses, over two wear periods (control then test). A washout period of 90 minutes between eyedrop instillations will occur. The second eyedrop as per the randomization schedule will follow the same procedure as previously stated. |
| Name | Type | Description |
|---|---|---|
| Blink® Tears eye drops in a multidose bottle | DRUG | Control |
| Preservative-free investigational lubricating eye drops in a Novelia® eyedropper | DRUG | Test |
Inclusion Criteria: * Potential subjects must satisfy all of the following criteria to be enrolled in the study: The subject must: 1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form. 2. Appear able and willing to adhere to the instruction...
Blink Tears is an investigational lubricating eye drop being studied for visual acuity in contact lens wearers. It is a small molecule in the ophthalmology therapeutic area. The product is delivered in a multidose bottle and is currently in Phase 2 clinical development.
Blink Tears is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The product is an investigational lubricating eye drop intended for use in contact lens wearers to assess visual acuity.
Blink Tears is in Phase 2 clinical development. It is an investigational product and has not been approved by regulatory authorities. One Phase 2 trial has been completed, and the product remains under clinical investigation for visual acuity in contact lens wearers.
Blink Tears has one completed Phase 2 clinical trial, registered as NCT05814367. The study, titled "Clinical Investigation of Visual Acuity in Contact Lens Wearers After Instillation of Investigational Lubricating Eye Drops," enrolled 46 healthy volunteers aged 18 years and older in the United States.
Blink Tears is not FDA approved. It is an investigational drug currently in Phase 2 clinical development. A single Phase 2 trial has been completed, but the product has not received marketing approval from the FDA or any other regulatory agency.